We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Precision BioSciences Inc | NASDAQ:DTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.09 | 12.00 | 12.75 | 20 | 12:52:42 |
- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.
Oral Presentation:
Title: Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate Hepatitis B virus in vivo Date and Time: Wednesday, October 12, 2022, 8:30 AM - 10:40 AM BST Session Title: Parallel 2a, Vaccine technologies & infectious diseases Location & Poster Number: Pentland and Sidlaw, OR14 Presenter: Derek Jantz, Ph.D., Chief Scientific Officer & Strategy
Poster Presentations:
Title: ARCUS gene editing of Apolipoprotein C3 results in substantial reduction in serum triglycerides in vivo Date and Time: Wednesday, October 12, 2022, 7:30 PM - 9:00 PM BST Session Title: Gene and epigenetic editing Location & Poster Number: Cromdale Hall, Level 2, Poster# P441 Presenter: Wendy Shoop, Scientist
Title: Specific elimination of m.3243A>G mutant mitochondrial DNA using mitoARCUS in cultured cells and a novel xenograft mouse model Date and Time: Thursday, October 13, 2022, 5:30 PM - 7:15 PM BST Session Title: Gene and epigenetic editing Location & Poster Number: Cromdale Hall, Level 2, Poster #P422 Presenter: Wendy Shoop, Scientist
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005408/en/
Investor Contact: Mei Burris Director, Investor Relations and Finance Mei.Burris@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com
1 Year Precision BioSciences Chart |
1 Month Precision BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions